<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000321385"><TermName>polyglutamate camptothecin</TermName><TermPronunciation>(PAH-lee-GLOO-tuh-mayt KAMP-toh-THEK-in)</TermPronunciation><TermDefinition><DefinitionText>A form of the anticancer drug camptothecin that may have fewer side effects and work better than camptothecin. It is being studied in the treatment of cancer. It is a type of DNA topoisomerase inhibitor. Also called CT-2106.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000711234" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;polyglutamate camptothecin&quot;" language="en" id="_3"/><MediaLink ref="CDR0000711235" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;poliglutamato de camptotecina&quot;" language="es" id="_4"/><SpanishTermName>poliglutamato de camptotecina</SpanishTermName><SpanishTermDefinition><DefinitionText>Tipo de camptotecina, un medicamento contra el cáncer que puede tener menos efectos secundarios y funcionar mejor que la camptotecina. Está en estudio para el tratamiento de cáncer. Es un tipo de inhibidor de la topoisomerasa del ADN. También se llama CT-2106.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2003-07-26</DateFirstPublished><DateLastModified>2007-05-17</DateLastModified></GlossaryTerm>
